RHA offers a collection of hyaluronic acid fillers with different indications, while Revanesse Versa is a specific filler for facial wrinkles and folds. This comparison separates the products by treatment area, formulation, clinical evidence, and safety.
The first distinction is the name on the syringe. Revanesse Versa contains no lidocaine, Versa+ contains lidocaine, and Lips+ carries a separate lip indication. RHA also has distinct products for folds, perioral lines, lips, cheeks, and under-eye hollows.
RHA Fillers vs Revanesse Versa at a Glance
The closest comparison for nasolabial folds is Versa or Versa+ against an RHA product labeled for that depth and indication. Comparing one Versa syringe with the entire RHA collection can obscure which products actually overlap.
| Factor | RHA Collection | Revanesse Versa / Versa+ |
| Manufacturer | Teoxane, Switzerland | Prollenium Medical Technologies, Canada |
| Filler material | Crosslinked hyaluronic acid | Crosslinked hyaluronic acid |
| Facial fold indication | Product-specific indications for dynamic facial wrinkles and folds | Moderate to severe facial wrinkles and folds, such as nasolabial folds |
| Additional labeled areas | Specific RHA products cover perioral lines, lips, cheeks, and infraorbital hollows | Lip augmentation belongs to the separate Lips+ product; Versa/Versa+ have no cheek or infraorbital indication |
| Local anesthetic | Revance currently distributes mepivacaine versions in the U.S. | None in Versa; 0.3% lidocaine in Versa+ |
| Syringe size | RHA 2 and RHA 3: 1.0 mL; Dynamic Volume: 1.2 mL | 1.0 mL and 1.2 mL configurations |
| Duration comparison | Product- and area-specific evidence | Product- and area-specific evidence; no direct longevity comparison with RHA identified |
Differences Between RHA and Revanesse Versa: Gel Design and Anesthetic
Both use crosslinked HA, but their manufacturing approaches and product ranges differ. Crosslinking joins HA molecules into a network that resists rapid breakdown.
What RHA’s Dynamic Design Means
Teoxane describes its Preserved Network Technology as a gentle, heatless process intended to preserve HA’s network structure. The design aims to accommodate facial movement, and several RHA labels specifically refer to dynamic wrinkles and folds.
That wording does not establish that other HA fillers cannot move with tissue. It also does not prove that every RHA product looks more natural than Versa in every area.
The clinically useful differences between RHA and Revanesse Versa involve the individual gel, its approved placement, and the problem being treated. A manufacturing description alone cannot determine the result.
Why the Anesthetic Matters
Revance currently distributes the RHA Collection with mepivacaine in the U.S., although FDA records also include earlier lidocaine-containing versions.
Versa+ contains 0.3% lidocaine. Original Versa has no added lidocaine, while Lips+ contains lidocaine.
Mepivacaine and lidocaine are both amide local anesthetics. Switching from Versa+ to RHA does not automatically resolve an amide-anesthetic allergy concern; the exact product contraindications and allergy history still govern selection.
RHA and Revanesse Versa Treatment Area Comparison
Treatment area provides the clearest reason to choose one product over another. The following table summarizes relevant U.S. indications rather than every use described on clinic websites.
| Treatment goal | Relevant RHA product | Relevant Revanesse product |
| Moderate to severe dynamic facial folds, including nasolabial folds | RHA 2, RHA 3, and Dynamic Volume, with product-specific placement | Versa or Versa+ for moderate to severe facial folds |
| Moderate to severe dynamic perioral lines | RHA Redensity | No corresponding specific perioral-rhytid indication identified for Versa/Versa+ |
| Lip augmentation and fullness | RHA 3 / RHA 3 Mepi; FDA-approved renamed version: RHA Kiss Volume | Lips+, rather than Versa/Versa+ |
| Cheek augmentation or age-related midface contour deficiency | Dynamic Volume; RHA 4 also holds this FDA indication | No corresponding Versa/Versa+ indication |
| Moderate to severe infraorbital tissue volume deficiency | RHA Redensity Eye | No corresponding indication; Versa/Versa+ instructions warn against injection into eye contours |
An RHA and Revanesse Versa treatment area comparison should keep perioral lines, lip volume, and under-eye hollows separate. They involve different tissues and product labels.
The RHA 4 family received an expanded cheek indication in 2025. The mepivacaine version, formerly RHA 4 Mepi, is now marketed as RHA Dynamic Volume in the U.S.
The FDA approved RHA Redensity Eye’s infraorbital indication on May 12, 2026. Announcement dates are not approval dates.
In July 2026, the FDA approved RHA Kiss Volume as the new commercial name for RHA 3 Mepi, along with updated needle options. The change did not create a new treatment indication.
RHA Redensity and RHA Redensity Eye are different products. The former treats dynamic perioral lines; the latter has the specific infraorbital indication.
Prollenium’s U.S. Revanesse product information distinguishes Versa, Versa+, and Lips+. Although Lips+ and Versa+ share the same formulation, their separate indications still matter.
How RHA Compares to Revanesse Versa in Clinical Use
Product-specific placement matters more than a general brand preference. RHA 2, RHA 3, and Versa/Versa+ overlap in mid-to-deep dermal fold correction; Dynamic Volume also has deeper fold and cheek indications.
The comparison therefore changes with the clinical goal. A comparison for nasolabial folds cannot settle the choice for superficial perioral lines or infraorbital volume deficiency.
For a suitable adult seeking fold correction, both brands provide labeled options. For cheek or infraorbital treatment within these two portfolios, the relevant RHA product has an indication that Versa lacks.
For lips, the comparison becomes RHA 3 or its mepivacaine version against Revanesse Lips+. Describing Versa+ as the U.S.-approved Revanesse lip product would conflate two labels.
Technique Follows the Product and Tissue Plane
The instructions for use specify the treatment plane and permitted equipment. A clinician should not transfer one product’s injection approach to another solely because both contain HA.
Nor does RHA’s dynamic design justify injecting any RHA gel into any moving facial area. Anatomy, product selection, and training remain necessary for each indication.
Which Lasts Longer, and Which Causes Less Swelling?
The available studies do not establish a universal longevity or swelling winner between RHA and Versa. Their trials used different protocols, comparators, and retreatment rules.
Follow-Up Length Is Not Single-Treatment Duration
The original RHA nasolabial-fold studies used a 24-week primary effectiveness endpoint and continued follow-up to 64 weeks. They allowed touch-ups and qualifying retreatments during follow-up.
The original Revanesse approval program also used a 24-week primary endpoint. Its extension included additional treatment at approximately six months and follow-up to 52 weeks.
Neither schedule means every patient retained the same correction from one injection throughout follow-up. A useful comparison distinguishes the assessment date, initial treatment response, and any additional treatment.
For counseling, use the duration evidence for the exact product and treatment area. RHA fold data cannot establish lip longevity, and a six-month Revanesse endpoint does not mean all results end at six months.
What the Swelling Figures Actually Show
The FDA’s original Revanesse approval summary reports injection-site swelling in 47.2% of subjects on the Revanesse side, versus 71.2% on the comparator side. This was a split-face nasolabial-fold study of 163 subjects.
Those figures represent a 24-percentage-point difference, or approximately 34% fewer swelling reports relative to the comparator. They do not mean half as much swelling, and they measure occurrence rather than swelling severity.
The comparator was not RHA. These results cannot establish that Versa or Versa+ causes less swelling than RHA, nor should original Versa trial rates be presented as a direct Versa+ versus RHA result.
Safety and Patient Selection for Providers
Both brands share the serious risk of accidental intravascular injection. Potential consequences include tissue necrosis, vision loss, and stroke.
Patient assessment should cover:
- Exact product contraindications: Severe allergy history, bacterial-protein sensitivity, anesthetic hypersensitivity, and other exclusions in the relevant instructions.
- Treatment-site condition: Active infection, inflammation, wounds, and relevant scarring.
- Medical and treatment history: Bleeding disorders, anticoagulant or antiplatelet use, previous filler, and recent procedures.
- Pregnancy or breastfeeding: Safety has not been established; follow each product’s restrictions.
- Expectations and follow-up: The intended correction, likely maintenance, and ability to recognize and report complications.
The restrictions are not interchangeable. For example, Versa+ instructions exclude patients receiving anticoagulant or antiplatelet therapy, while RHA’s general safety information describes increased bruising or bleeding with such medicines.
That difference requires product-specific assessment. It is not a reason for a patient to stop prescribed medication to receive elective filler.
HA degradability does not guarantee reversal of an injury. A practice needs trained staff, an established complication response, and prompt escalation for suspected vascular compromise.
The FDA dermal filler guidance explains common reactions and serious complications. Specific FDA product approvals supply the indications for newer products such as Redensity Eye.
Syringe Volume, Wholesale Cost, and Inventory
A larger syringe lowers acquisition cost per milliliter only when the price comparison supports it. It does not establish better clinical value or justify injecting more gel.
Versa+ has 1.0 mL and 1.2 mL configurations. RHA 2 and RHA 3 have 1.0 mL syringes, while Dynamic Volume has a 1.2 mL syringe.
A 1.2 mL syringe contains 20% more gel than a 1.0 mL syringe. That comparison applies to those volumes, not to Versa against every RHA product.
Acquisition cost per mL = syringe purchase price ÷ labeled syringe volume.
A practice also needs to account for unopened stock that expires, unused gel after treatment, shipping, and repeat-treatment requirements. Lower unit cost cannot compensate for an unsuitable product or an unverified source.
Stocking both brands can support different treatment goals, but overlapping fold products do not automatically require duplicate inventory. The useful question is whether each stocked product has a defined role in the practice’s case mix.
How to Verify Product Sources
Manufacturer confirmation is more useful than a supplier’s FDA-approved badge. It helps establish whether the exact product and seller belong to the U.S. supply channel.
Revance identifies itself as the exclusive U.S. distributor of the Teoxane RHA Collection. For Revanesse, a clinic can confirm the supplier’s status directly with Prollenium using the Prollenium manufacturer information site.
Verification should cover the U.S. product name, manufacturer, lot, expiration, sealed packaging, and current instructions for use. Documented shipping and storage conditions also matter.
International names or packaging warrant further verification. They do not, by themselves, prove counterfeiting, and a genuine product sold in another country is not automatically the same U.S.-approved presentation.
Adding Revanesse Versa to Your Filler Inventory
For practices evaluating HA fillers for moderate to severe facial wrinkles and folds, Revanesse Versa offers a focused option within an injectable inventory. Product selection should still reflect the intended treatment area, patient needs, and the exact Revanesse formulation required.
Licensed medical practices can source wholesale Revanesse Versa through DeWitt Pharma, with credential verification and nationwide fulfillment for eligible providers.
Final Thoughts
RHA and Revanesse Versa are both HA-based options, but they should not be treated as interchangeable products. RHA is a broader collection with product-specific indications, while Versa and Versa+ focus on moderate to severe facial wrinkles and folds.
The best choice depends on the treatment area, formulation, patient needs, and applicable labeling. Not from a single claim about longevity, swelling, or price.
Frequently Asked Questions
What is the main difference between RHA Fillers and Revanesse Versa?
The central distinction is that RHA is a collection of HA fillers, while Revanesse Versa is a specific filler for facial wrinkles and folds. Differences include product-specific indications, anesthetics, and syringe configurations. Wider RHA portfolio coverage does not mean every RHA gel suits every treatment area.
Which option lasts longer, RHA Fillers or Revanesse Versa?
A direct longevity comparison was not identified in the sources reviewed. RHA fold studies followed patients to 64 weeks, while the Revanesse program included a 52-week extension, but touch-ups and retreatment prevent treating those periods as guaranteed single-injection duration.
How do treatment goals affect product choice?
Both portfolios offer options for facial fold correction. Other treatment goals require looking at the exact product. Specific RHA products have indications for areas such as perioral lines, cheeks, and infraorbital hollows, while Revanesse Lips+ provides the separate Revanesse option for lip augmentation.
Which product is better for first-time patients?
Whether RHA or Revanesse Versa is better for a first-time patient depends on the indicated area, anatomy, medical history, and desired correction. First-time status alone does not establish an advantage for either brand.
How do injection techniques differ between these products?
Technique depends on the individual formulation and labeled tissue plane. RHA 2, RHA 3, and Versa/Versa+ overlap in mid-to-deep dermal fold treatment, while other RHA products have different placement instructions.
What safety factors should providers compare?
Providers should check exact contraindications, anesthetic allergies, treatment-site health, previous procedures, and complication preparedness. Neither brand removes the risk of vascular occlusion, and the Revanesse comparator swelling study does not establish superiority over RHA.
How do wholesale costs affect product selection?
Wholesale cost helps compare acquisition expense after clinical suitability is established. Price per milliliter, labeled syringe volume, wasted product, and inventory turnover provide more useful context than price per box alone.
Can both products be stocked in one clinic?
Yes. A clinic can stock both when each product has a defined clinical role and a verified source. Duplicate fold inventory is useful only if its benefits justify the additional storage, training, and expiration management.
What patient factors influence the final choice?
Relevant factors include age, treatment area, tissue characteristics, prior filler, allergy history, medicines, infection or inflammation, and expectations. Some findings may rule out treatment rather than simply favoring another brand.
Where can licensed clinics order Revanesse Versa?
Licensed medical practices can order Revanesse Versa through DeWitt Pharma. Practices should confirm the exact Revanesse product required, verify current labeling, and maintain appropriate lot and acquisition records.
DeWitt Pharma verifies professional credentials and provides nationwide fulfillment for eligible medical practices.
